Table 5.

Risk factor analysis for overall and cancer-specific survival in patients undergoing esophagectomy for cancer

VARIABLE	OVERALL SURVIVAL				CANCER-SPECIFIC SURVIVAL
	Univariate		Multivariate		Univariate		Multivariate
	HR (CI 95%)	p value	HR (CI 95%)	p value	HR (CI 95%)	p value	HR (CI 95%)	p value
Age
<70 years	1.00		1.00		1.00		1.00
70–79 years	1.79 (1.33–2.41)	<0.001	1.50 (1.07–2.11)	0.020	1.86 (1.29–2.69)	0.001	1.50 (0.97–2.31)	0.068
≥80 years	1.98 (0.96–4.05)	0.063	2.99 (1.40–6.38)	0.005	2.45 (1.18–5.08)	0.016	3.49 (1.59–7.68)	0.002
Gender
Female	1.00		1.00		1.00		1.00
Male	1.04 (0.72–1.49)	0.830	1.09 (0.73–1.63)	0.676	0.92 (0.61–1.40)	0.704	1.05 (0.65–1.69)	0.842
Histology
High-grade dysplasia	1.00		1.00		1.00		1.00
Adenocarcinoma	4.10 (1.30–12.87)	0.016	4.20 (0.67–26.20)	0.124	3.53 (0.87–14.32)	0.078	4.92 (0.47–51.70)	0.184
Squamous cell carcinoma	4.69 (1.43–15.37)	0.011	3.55 (0.54–23.17)	0.186	4.37 (1.02–18.76)	0.047	4.05 (0.36–45.14)	0.256
Cancer Stage
Stage 0	1.00		1.00		1.00		1.00
Stage I	0.60 (0.31–1.15)	0.122	0.42 (0.11–1.61)	0.207	0.45 (0.21–0.96)	0.038	0.34 (0.08–1.45)	0.145
Stage II	1.36 (0.73–2.56)	0.335	0.91 (0.24–3.41)	0.885	1.07 (0.52–2.19)	0.856	0.79 (0.19–3.28)	0.749
Stage III	2.97 (1.61–5.46)	<0.001	1.99 (0.54–7.37)	0.301	2.64 (1.34–5.19)	0.005	2.03 (0.50–8.16)	0.319
Stage IV	3.81 (1.23–11.85)	0.021	3.17 (0.59–17.01)	0.178	4.29 (1.18–15.66)	0.027	4.41 (0.69–28.22)	0.117
Neoadjuvant therapy	1.22 (1.05–1.41)	0.007	1.17 (0.98–1.38)	0.072	1.20 (1.01–1.44)	0.040	1.22 (0.98–1.51)	0.071
Postoperative major morbidity	1.69 (1.27–2.25)	<0.001	1.57 (1.14–2.15)	0.005	2.01 (1.41–2.86)	<0.001	2.07 (1.39–3.07)	<0.001